Expertise in
2
conditions

Dr. Devansu Tewari

Oncology | Obstetrics and Gynecology
Kaiser Permanente
Alton/sand Canyon Medical Offices
6650 Alton Pkwy, 
Irvine, CA 
Accepting New Patients
Expertise in
2
conditions
Kaiser Permanente
Alton/sand Canyon Medical Offices
6650 Alton Pkwy, 
Irvine, CA 

Overview

Devansu Tewari is an Oncologist and an Obstetrics and Gynecologist practicing medicine in Irvine, California.

Dr. Tewari is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Human Papillomavirus Infection, Ovarian Cancer, Cervical Cancer, and Vaginal Cancer.

He is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 3 clinical trials. Dr. Tewari is currently accepting new patients.

Specialties

Oncology
Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in OR

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Alton/sand Canyon Medical Offices
6650 Alton Pkwy, Irvine, CA 92618

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
Enrollment Status: Completed
Publish Date: April 05, 2023
Intervention Type: Drug, Biological
Study Drugs: Vigil Tumor Cells, Atezolizumab
Study Phase: Phase 2
View 2 Less Clinical Trials

17 Total Publications

Factors accounting for excess uterine cancer mortality among insured Black versus White patients treated within the same US health care system.
Factors accounting for excess uterine cancer mortality among insured Black versus White patients treated within the same US health care system.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: November 20, 2025
Similar Doctors
Expertise in
36
conditions
Dr. Tanya Siddiqi
Oncology
Expertise in
36
conditions
Dr. Tanya Siddiqi
Oncology
Referral may be required

Tanya Siddiqi, M.D.

Irvine, CA 
 (13.9 miles away)
847-342-6842
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tanya Siddiqi is an Oncologist practicing medicine in Irvine, California. Dr. Siddiqi is highly rated in 36 conditions, according to our data. Her clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
25
conditions
Dr. Sumanta Pal
Oncology
Expertise in
25
conditions
Dr. Sumanta Pal
Oncology
Referral may be required

Sumanta Kumar Pal, M.D., Fasco

Irvine, CA 
 (13.9 miles away)
847-342-6842
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sumanta Pal is an Oncologist practicing medicine in Irvine, California. Dr. Pal is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Expertise in
18
conditions
Dr. Krishnansu S. Tewari
Oncology
Expertise in
18
conditions
Dr. Krishnansu S. Tewari
Oncology
Referral may be required
1000 West La Veta Avenue, Floor 1, 
Orange, CA 
 (6.8 miles away)
714-734-6225
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Krishnansu Tewari is an Oncologist practicing medicine in Orange, California. Dr. Tewari is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Lymphadenectomy. Dr. Tewari is currently accepting new patients.

Frequently Asked Questions about Dr. Devansu Tewari

How do I make an appointment with Dr. Devansu Tewari?

You can book an appointment with Dr. Devansu Tewari by calling their office at 833-574-2273. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Devansu Tewari a top-rated expert for Human Papillomavirus Infection?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Devansu Tewari is classified as an Advanced expert for Human Papillomavirus Infection, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Devansu Tewari specialize in?

While Dr. Devansu Tewari is a Oncology, they have specific expertise in Human Papillomavirus Infection, Ovarian Cancer, and Cervical Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Devansu Tewari participate in research or clinical trials?

Yes. Dr. Devansu Tewari has published 17 articles and abstracts on conditions like Human Papillomavirus Infection. You can view a list of Dr. Devansu Tewari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tewari's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile